Upload
others
View
2
Download
0
Embed Size (px)
Citation preview
1
1
partnering to deliver Impact
1
Dr. Emily Vereker
Technology Transfer Case Manager,
Trinity College Dublin
Office of Corporate
Partnership & Knowledge
Exchange
2
22
ideas - innovation - entrepreneurship - knowledge transfer
2
290INVENTIONS
70LICENCES TO
INDUSTRY
38CAMPUS COMPANIES
TRINITY’S DEVELOPMENT PIPELINE (2008 – 2013)
3
33
a new perspective – industry
Technology Transfer PartnershipKnowledge Exchange
4
44
shift in business model
4
“….R&D is not a monolithic enterprise any longer, but more of a flexible function that finds the
innovation necessary to address each market’s need….”
- Christopher Bowe, US healthcare analyst for Informa’s Scrip Intelligence
5
55
industry challenges - academic enablers
patent cliffs
5
state funding
patent portfolio
R&D
infrastructure
CHALLENGES ENABLERS
graduates
business model shift for efficiency & economy
market shift, policy shift
managing shiftsin research focus
budgetary constraints
IP creation
early go-no-go decisions
R&D
Know how
& equipment
hospital /clinicalaffiliations
assays, processes methodologies
6
66
principles for engagement
open innovation - we want the IP to be practiced
not profit motivated - knowledge transfer for
socio-economic return
flexibility - open to a range of
mutually beneficial models for IP ownership
user-friendly - systems in place to
support and encourage engagement
practical - we want to do fair, quick deals
6
7
77
history of industrial partnerships
7
Global Innovative Companies
TCD collaborates with
14 of the top 20
Medical Device Companies
TCD collaborates with
8 of the top 10
ICT exporters in Ireland
TCD collaborates with
8 of the top 10
Trinity entered into
100 research agreements
with industry in 2012
8
88
top 30 collaborating companies 2008 - 2013
8
1 Intel 16 Amgen
2 Glaxo Smithkline 17 BASF
3 Applied Biosystems 18 Centocor
4 Boehringer Ingelheim 19 Dow Corning
5 Novartis 20 Dupont
6 Merck & Co. 21 Glantreo
7 Genetech 22 Brunker
8 Alere Technologies 23 Neurosearch
9 River Diagnostics 24 Henkel
10 Novo Nordisk 25 Alex Pharmaceuticals
11 Pfizer 26 Analysis Group
12 IBM 27 Astrazeneca
13 Clavis Pharma 28 Biofluidix
14 Norchip 29 European Central Bank
14 Vale Inco 30 Hewlett Packard
9
99
Trinity Biomedical Sciences Institute - Open Innovation
55PIs with labs
VITAL STATISTICS
520number of researchers
21,000m2
academic & teaching space
€10mvalue of equipment
3centers of research excellence
5schools
10
10
interdisciplinary competencies
TBSI immunology & biochemistry
pharmacy
chemistry
bioengineering
medicine
Cancer
medical devices
11
11
competencies
co
mp
ete
ncie
s
design
bio-engineering
neural engineering
electronics
Software
instruments
prototyping
target identification
medicinal chemistry
formulation
pathway/moa
animal model
transgenicso
utp
uts
stents
inhalers
bio-orthopaedics
Prosthetics
biomaterials
immuno therapeutics
cancer therapeutics
vaccines
adjuvants
new chemical entities
biomarkers
diagnostics
prognostics
efficiencies in care
12
1212
early drug discovery to validation capabilities
drug
candidate
-
in vivo
efficacy
preclinical development
in vitro efficacy
-
cellular disease assays
-
mechanism of action
-
pathways
cellular & molecular
pharmacology
library development
-
structure-based design optimisation
-
medicinal chemistry
medicinal chemistry
binding assays
-
high throughput screening
-
biochemical assays
lead discovery
structure determination
-
nmr
-
crystallog’y
-
mass spec
informatics & genomics
isolaton
-
purification
-
validation
target discovery
research target IDtarget
validat’nscreening
pre-clinical
Clinical Ph I, II, III
regulatory
13
13
case study - SIGMOID PHARMA
challenges
engagement type
Regular collaborations, availing of State funding; ‘Enterprise Partnership Scheme’, ‘Innovation Partnership Program’, contract research services and an FP7 partner
impact“..collaborating with the Lavelle group, the potential of SmPill® to enable oral vaccination has been proven…..allow Sigmoid to support its existing intellectual property portfolio, further characterise various vaccine formulations, complete pre-clinical development, and create new academic collaborative as well as commercialisation opportunities
critical enablers
Knowhow in the evaluation of innate and adaptive immuneresponses induced by mucosal adjuvants and in dissectingthe underlying mechanisms of adjuvanticity.
proprietary Single-multiple Pill (SmPill®) enables the combining of antigenic and adjuvant materials within an emulsion to permit the development of oral vaccines.
Requires assistance with design and evaluation of adjuvants,associated challenge models and infrastructure
14
1414
current industrial engagement
€700kOrla Hardiman
– Elan, Merck, Biogen, Novartis
€250kAnn Molloy – Axis Shield
~80industry collaborators
€500kMartin Caffrey
– B&I
€10mSFI – Industry funded
AMBER center
€350kDr.
– Company Y
15
1515
Dr. Emily Vereker
Technology Transfer Case Manager,
Trinity College Dublin
https://www.tcd.ie/biosciences/
http://www.tcd.ie/innovation/
(01) 896-4152
16
16
case study - ALKERMES, INC
challenge
engagement type
The Alkermes-Trinity research services engagement is adirect industry funded project. IP owned by Alkermes
impact“Leveraging existing state-of-the-art neurological techniques and scientific expertise advantageously strengthens our drug development profile and allows for rapid critical go/no-go decisions to be made”
critical enablers
Extensive technical expertise in the areas of learning andmemory, mechanisms of brain repair, drug action in the CNSand synaptic plasticity
unmet needs, debilitating diseases of the central nervous system (CNS), such as schizophrenia, addiction and depression.
• Requires assistance with progressing medicines morerapidly from discovery to development
• Alkermes Inc establishes new partnerships and leveragesestablished science as a key strategy
17
17
competencies
High throughput | virtual screening
Amir Chan
Martin Caffrey
Darren Fayne
modification
Mike Southern
Isabel Rozas
optimisation
M.Meegan
D.Zisterer
in vivo efficacy
target identification | isolation
L.O’Driscoll
M. Caffrey
D. Fayne
function determination
C.O’Farrelly
K. Mills
assay | pathway
K. Mills
L.O’Neill
C. Gardiner
in vivo efficacy
P.Fallon
E. Lavelle
feasibility
B.Murphy
D. Kelly
design verification
R. Reilly
Simmons
prototype
Prendergast
validation
devices
targets
biomarkers
drug
discovery
18
1818
early discovery to validation capabilities
identification
function determination
biochemical assays
in vivo validation
HTS virtual
screening
selection
modification
optimisation
in vivo efficacy
TARGETSBIOMARKERS
DRUG DISCOVERY
MEDICAL DEVICE
feasibility
design
verification
prototype
validation
19
1919
equipment & facilities
800MHz NMR with multiple probes
including cold probe
Tissue Culture Lab Confocal Microscopy
Fluorescent Activated Cells Sorter (FACS) Anatomy Teaching Lab Biochemistry Labs